
Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review

Dr Tim Lewens


Member of Council and Member of the Working Party on mitochondrial donation



Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review

Mitochondria

- Mitochondria: the 'batteries of a cell'
- Contain their own DNA system (mtDNA)
- Maternally inherited
- Mutation rate about ten times that of nDNA



Mitochondrial DNA disorders

- Inherited genetic disorders caused by mutations
 in mitochondrial DNA
- Progressive disorders can onset from any age from birth and there is currently no cure
- Can cause debilitating and disabling health problems including heart failure, stroke, blindness, deafness, muscle weakness
- Severe forms can lead to death in early infancy and affect approximately one in 6,500 infants.


Current options


• Preventing transmission

- Transmission is complex and hard to predict
- Only definite option is to avoid using own eggs (egg donation, surrogacy or adoption)
- Minimising risk
 - Preimplantation genetic diagnosis (PGD)
 - Prenatal diagnosis (PND)

Novel techniques: the context

- The UK is at the forefront of research on new techniques to prevent transmission
- The techniques are currently unlawful but regulatory-making powers exist that could enable the Secretary of State to permit these techniques in future
- The HFEA started a public dialogue on the issues shortly after we published our report, they will report findings in 2013
- A possible debate in Parliament?





Ethical considerations

Potential benefits

- Opportunity for parents to have genetically related children
- Children potentially born free from mitochondrial disorders, and descendents of any women born via these therapies

Ethical questions

- PNT and MST are forms of germline therapy
 - \rightarrow 'slippery slope'?
- Uncertainty-potential harm?
- Issues of identity: confused self-image?
- Novel social and family relationships

Working group conclusions

- If proved safe and effective, and if appropriate information and support is offered, it would be ethical for families to use these techniques as treatment
- Subject to appropriate oversight, it is ethical to gather further information about these techniques for them to be considered for treatment use

Further conclusions

Parentage of the child

• Not legally or biologically accurate to refer to as 'mother' or 'third parent'

Status of the donor

 Mitochondrial donors should not have same status as donors of egg or embryo for reproduction – e.g. be mandatorily identifiable

Further conclusions (cont.)

If these techniques are approved for treatment in future:

- Information and counselling must be provided
- Follow up and evaluation is crucial, could be supported by centrally funded register of all UK procedures
- Should only be offered as part of a clinical trial in specialist centres

Further issues for discussion

- We consider this to be a form of germline therapy
- The wider policy debate could benefit from a fuller discussion of the ethics of the different kinds of prospective and theoretical germline therapies than was possible within the remit of this report

NUFFIELD COUNCIL[™] BIOETHICS

www.nuffieldbioethics.org/mitochondria